Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast Track vs Conventional Treatment for Colorectal Cancer
NCT01080547Phase 3Completed
- Sponsor
- Zhejiang University
- Start
- Mar 2010
- Primary completion
- Apr 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colorectal cancer (CRC) (4 arms), sponsored by Zhejiang University. Primary endpoint: Hospitalization Day at 6 months. Started Mar 2010; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01080547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01080547.